Raymond James analyst Dane Leone maintained a Buy rating on Bristol Myers (BMY) today. The company’s shares closed last Tuesday at $61.27.
According to TipRanks.com, Leone is a 5-star analyst with an average return of 18.2% and a 65.8% success rate. Leone covers the Healthcare sector, focusing on stocks such as Adverum Biotechnologies, Tarsus Pharmaceuticals, and Allogene Therapeutics.
Currently, the analyst consensus on Bristol Myers is a Strong Buy with an average price target of $78.25, representing a 26.3% upside. In a report issued on February 16, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $67.16 and a one-year low of $45.76. Currently, Bristol Myers has an average volume of 11.67M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The firm offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
Read More on BMY:
